Thursday May 9
Biocryst Pharmaceuticals to Present at Two Upcoming Investor Conferences
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals (BCRX) Releases Quarterly Earnings, Beats Estimates By $0.06 EPS
BioCryst Pharmaceuticals posted its quarterly earnings results on Tuesday. The company reported earnings per share for the quarter, beating the analysts' consensus estimate of by $0.06, StockRatingsNetwork reports.
BioCryst Provides Corporate Update and Reports First Quarter 2013 Financial Results
"We are pleased that our recent interactions with the FDA have defined a pathway to file a peramivir NDA for regulatory approval in the U.S.," said Jon P. Stonehouse, President & Chief Executive Officer of BioCryst.
Before the Bell Scans of PDLI, BCRX, ARRY, and RPRX
The "patent cliff", which refers to the expiration of patent on several blockbuster drugs over the next few years, is having a significant impact on major drug companies' top-lines. According to estimates from EvaluatePharma, in 2013 alone, patents on drugs with annual sales of nearly $29 billion will expire.
Editor's Picks: 10 best stories in April
April was a month that kept our reporters and editors busy chasing down stories that could have a major economic impact on our region in the coming years.
BioCryst Heats Up: H7N9 Virus Hits Taiwan, Fatalities Up Nearly 300%
We've been seeing a lot of new activity in BioCryst Pharmaceuticals , which we last covered on April 7th following a 42% run in the stock chasing the good news that the company received from the FDA about its antiviral agent peramivir .
Commentary & Reports For:
BioCryst Pharmaceuticals Inc. traded in the range of $1.75 and $1.97 during its latest trading session.
BioCryst shares rise after flu news
That flu has led to the approval of BioCryst 's flu treatment peramivir in China, despite the drug's failure to meet endpoints in its FDA trial.